TCGA-91-8497-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.370
- PANCREAS_BETA_CELLS+0.360
- MYOGENESIS+0.270
- BILE_ACID_METABOLISM+0.260
- COAGULATION+0.170
- IL6_JAK_STAT3_SIGNALING+0.160
- KRAS_SIGNALING_UP+0.150
- KRAS_SIGNALING_DN+0.130
- WNT_BETA_CATENIN_SIGNALING+0.130
- ALLOGRAFT_REJECTION+0.120
Top 10 suppressed
- E2F_TARGETS-0.730
- MYC_TARGETS_V1-0.710
- G2M_CHECKPOINT-0.650
- MYC_TARGETS_V2-0.620
- MTORC1_SIGNALING-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.480
- DNA_REPAIR-0.470
- GLYCOLYSIS-0.410
- PROTEIN_SECRETION-0.400
- MITOTIC_SPINDLE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-97-7941-01A-11R-2187-07 | — | cohortA1 | 0.922 |
| 2 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.915 |
| 3 | TCGA-NJ-A55O-01A-11R-A262-07 | — | cohortA2 | 0.904 |
| 4 | TCGA-97-A4M5-01A-11R-A24X-07 | — | cohortA1 | 0.897 |
| 5 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.893 |
| 6 | TCGA-75-7025-01A-12R-1949-07 | — | cohortA1 | 0.891 |
| 7 | TCGA-NJ-A55A-01A-11R-A262-07 | — | cohortA1 | 0.891 |
| 8 | SRR1313109 | — | A | 0.890 |
| 9 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.889 |
| 10 | C3L-03268 | — | cohortA1 | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |